Counting the cost of Alzheimer’s disease Mark Greener Newsletter Article 11 February 2013 Pages: 3 - 4
Guideline development alone does not ensure use in practice Newsletter Article 11 February 2013 Pages: 4 - 4
Consider cost impact of palivizumab in RSV infection Newsletter Article 11 February 2013 Pages: 5 - 5
Community commitment needed for ivermectin programme in Africa Newsletter Article 11 February 2013 Pages: 5 - 5
Recommendations for economic evaluation in rheumatoid arthritis Newsletter Article 11 February 2013 Pages: 6 - 6
Pravastatin cost effective for prevention of coronary disorders Newsletter Article 11 February 2013 Pages: 7 - 7
Compliance with antihypertensives poor in clinical practice Newsletter Article 11 February 2013 Pages: 8 - 8
Albendazole cost effective for intestinal parasites in US immigrants Newsletter Article 11 February 2013 Pages: 9 - 9
International study shows treatment of acute MI suboptimal Newsletter Article 11 February 2013 Pages: 10 - 10
Better QOL with oxaprozin in osteoarthritis of the knee Newsletter Article 11 February 2013 Pages: 10 - 10
New Zealand’s preferred supplier policy criticised Newsletter Article 11 February 2013 Pages: 11 - 11